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ABSTRACT 
Objective. The initial aim of this study was to generate a transplantable glial tumour model of low-
intermediate grade by disaggregation of a spontaneous tumour mass from genetically engineered mice 
(GEM). This should result in an increased tumour incidence in comparison to GEM animals. Methods. An 
anaplastic oligoastrocytoma (OA) tumour of WHO grade III was obtained from a female GEM mouse 
-v-erbB/inK4a-Arf (+/-) genotype maintained in the C57BL/6 background. The tumour 
tissue was disaggregated; tumour cells from it were grown in aggregates and stereotactically injected into 
C57BL/6 mice. Tumour development was followed using Magnetic Resonance Imaging (MRI), while 
changes in the metabolomics pattern of the masses were evaluated by Magnetic Resonance 
Spectroscopy/Spectroscopic Imaging (MRS/MRSI). Final tumour grade was evaluated by 
histopathological analysis. Results. The total number of tumours generated from GEM cells from 
disaggregated tumour (CDT) was 67 with up to 100% penetrance, as compared to 16% in the local GEM 
model, with an average survival time of 66±55 days, up to 4.3-fold significantly higher than the standard 
GL261 glioblastoma (GBM) tumour model. Tumours produced by transplantation of cells freshly 
obtained from disaggregated GEM tumour were diagnosed as WHO grade III anaplastic 
oligodendroglioma (ODG) and OA, while tumours produced from a previously frozen sample were 
diagnosed as WHO grade IV GBM. Conclusions. We successfully grew CDT and generated tumours 
from a grade III GEM glial tumour. Freezing and cell culture protocols produced progression to grade IV 
GBM, which makes the developed transplantable model qualify as potential secondary GBM model in 
mice. 
KEYWORDS 
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ABBREVIATION LIST 
BBB, Blood-brain barrier; CDT, Cells from disaggregated tumour; CE, Contrast-enhanced; Cho, Choline; 
Cr, Creatine; DCE, Dynamic contrast enhancement; DMSO, Dimethyl sulfoxide; FASTMAP, Fast 
Automatic Shimming Technique By Mapping Along Projections; GABRMN, Grup d'Aplicacions 
Biomèdiques de la Ressonància Magnètica Nuclear; GBM, Glioblastoma; GEM, Genetically engineered 
mice; GFAP, Glial fibrillary acid protein; Glc, D-glucose; ip, intraperitoneal; IST, inter-slice thickness; 
KO, knocked out; Lac, Lactate; LET, Long echo time; ML, Mobile lipids; MR, Magnetic Resonance; 
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MRI, Magnetic Resonance Imaging; MRS, Magnetic Resonance Spectroscopy; MRSI, Magnetic 
Resonance Spectroscopic Imaging; NA, Number of averages; NAA, N-acetylaspartate; OA, 
Oligoastrocytoma; ODG, Oligodendroglioma; Olig2, Oligodendrocyte transcription factor; PBS, 
Phosphate Buffered Saline; PCR, Polymerase chain reaction; PE-MRSI, Perturbation enhanced MRSI; 
p.i., Post-implantation; PR, Pattern recognition; PRESS, Point-resolved spectroscopy; RARE, Rapid 
Acquisition with Relaxation Enhancement; SD, Standard deviation; SET, Short echo time; spv, spectral 
vector; ST, Slice thickness; SV, Single voxel, TAT, Total Acquisition Time; Tau, Taurine; TE, Echo 
Time; TR, Recycling Time; UL, Unit Length; VAPOR, Variable pulse power and optimized relaxation 
delays; VOI, Volume of interest; WHO World Health Organization 
INTRODUCTION 
Gliomas are one of the most life threatening and the most common primary human brain 
malignancies with annual incidence of ~5 cases per 100,000 people [1,2]. Despite advancements in 
surgery and adjuvant therapy, the prognosis remains very poor, with a median survival of less than 15 
months for glioblastoma (GBM) [3], and 3-7 years for anaplastic glial tumours [4-6]. 
Improvement of diagnosis and therapeutics requires reliable animal glioma models, and many 
have been developed for this purpose. They can be divided into genetically engineered models (GEM) 
and engrafted tumour models. GEMs allow recapitulating specific genetic patterns of primary human 
glioma [7,8]. However, late and stochastic onset and the inherent difficulty to detect brain masses in a 
timely fashion make them impractical for therapy response studies [9]. Additionally, the incidence of 
GEM tumours may be smaller than incidence achieved in transplantable models [7,10,11] and may vary 
with time or with crosses because of genetic background problems, while the stereotactic injection models 
maintain almost full penetrance. Due to high penetrance and reproducible tumour growth, the engrafted 
models are the most used for evaluating new therapies for glioma. To combine advantages of both 
models, transplantable models derived from GEM have been used [12,13].  
In vivo characterisation and monitoring of brain tumours, alongside with development of new 
cancer models, is of major importance for progression or therapy response studies. In this respect, 
Magnetic Resonance Imaging (MRI) is the most used technique for diagnosis and management of brain 
tumours, providing detailed anatomic information [14,15]. This can be supported by Magnetic Resonance 
Spectroscopy (MRS) and Spectroscopic Imaging (MRSI), which allow collecting non-invasive 
biomarkers, that may provide important clues about tumour biology and response to treatment [16,17]. 
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Single voxel (SV) MRS measures the average metabolic information of a tumour [16,17], whereas 
multivoxel acquisition (MRSI) provides spatially resolved metabolic information [18-20], which may be 
superimposed to anatomical acquisitions. Additionally, our group has developed MRSI-based molecular 
imaging techniques, perturbing the spectral pattern (Perturbation Enhanced Magnetic Resonance 
Spectroscopic Imaging, PE-MRSI) by injecting different substances, such as dimethyl sulfoxide (DMSO) 
and glucose [21-23], to increase the dynamic range for in vivo preclinical brain tumour characterization.  
In this work we have attempted to establish a low/intermediate grade transplantable glioma 
model by disaggregation of a GEM brain mass and to characterise this tumour model through magnetic 
resonance techniques. 
MATERIALS AND METHODS 
GL261 cell culture  
The murine GL261 glioma cell line was obtained from the Tumour Bank Repository at the 
National Cancer Institute (Frederick/MD, USA). Cells were grown as previously described [22].  
Animals  
A total of 86 C57BL/6 female mice of 18-24g in weight, aged 16-20 weeks, obtained from 
this study.  
-v-erbB/inK4a-Arf (+/-) genotype maintained in the 
C57BL/6 background) were obtained through the Mouse Models of Human Cancer Consortium 
Repository at the National Cancer Institute (MMHCC-NCI, Frederick, MD, USA) [24]. A spontaneous 
tumour developed in a GEM mouse, diagnosed as anaplastic OA (details in results section), was used to 
grow the culture of cells from disaggregated tumour (CDT).  
All mice were housed in the animal facility of Universitat Autònoma de Barcelona (Servei 
d'Estabulari). Studies were approved by the local ethics committee (protocols CEEAH 1176 and 2449). 
CDT culture  
Mice were sacrificed by cervical dislocation, and tumours were excised and disaggregated 
mechanically with a fire-polished Pasteur pipette. CDT were grown as aggregates and some CDT 
aggregates were frozen to check the reliability and repeatability of cultured cells for transplantation 
purposes. CDT culture conditions are described in the Supplementary Material file.  
Tumour generation 
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C57BL/6 mice (n=86) were divided into 6 groups (summarized in Supplementary Table 1). For 
set-up studies with GL261 tumours, 19 animals were used: 6 animals implanted with GL261 cells for 
standard GBM generation (group A); 13 animals injected with CDT cultured from GL261 tumours from 
A  group (6 from fresh and 7 from tumour frozen in liquid N2 for 6 months, groups B and C 
respectively). For GEM tumour studies, 67 animals were used: 29 animals (group D) implanted with CDT 
cultured from the freshly extracted S912 tumour (referred to as fresh CDT); a further group of 29 animals 
(group E) implanted with CDT obtained from S912 tumour, in which CDT aggregates were frozen in 
liquid N2 during 5 months, thawed and recultured prior to implantation (referred to as frozen CDT); and 
finally, 9 mice implanted with CDT obtained from a frozen piece of S912 tumour (group F). . 
Tumours were induced in mice as previously reported [22], either from GL261 cultured cells or 
CDT. In case of tumours generated from fresh CDT, cells were not counted before implantation, but it 
was assumed that each well of the multi-well plate contained ~105, considering cell counting before 
seeding and their assumed proliferation rate.  
MR studies 
All MR studies were performed at UNIT 25 of NANBIOSIS, a joint NMR facility of the 
Universitat Autònoma de Barcelona and CIBER-BBN (Cerdanyola del Vallès, Spain). The 
MRI/MRS/MRSI sequences and MR data post-processing are detailed in the Supplementary Material file. 
Briefly, coronal high resolution T2W images were acquired every 3-6 days during the first month of 
tumour evolution, starting on day 9 post-implantation (p.i.), and every 15 days thereafter if a mass was 
not detected. SV spectra were acquired at short and long echo time. Tumour-bearing mice were also 
studied by PE-MRSI with DMSO [21] and/or with glucose under mild hypothermia [22,23]. Blood brain 
barrier (BBB) integrity was evaluated with gadoterate meglumine (DOTAREM, Guerbet, Roissy, France) 
using contrast-enhanced (CE) T1W images.  
Tissue preservation for post-mortem procedures 
In vivo MR studies and tumour progression follow up took place until animals died or were 
sacrificed, due to animal welfare protocol, by cervical dislocation. The brains of 49 mice were excised 
and fixed in 4% formaldehyde. Further details are described in the Supplementary Material file. 
Genotype check 
Transgene presence and knock-out mutations of the GEM S912 mouse and selected S912-
derived tumours were checked by polymerase chain reaction (PCR) analysis performed on DNA 
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extractions from a piece of tail or tumour, respectively. Technical details can be found at Supplementary 
Material file. 
Statistics 
Detailed information about statistical tests can be found in the Supplementary Material file.  
RESULTS 
Passage of tumours obtained from disaggregation of GL261 GBM
GL261 tumour-bearing mice were sacrificed once masses reached a volume of 140±20 mm3 
(n=6, day 18±2 p.i.) and tumour tissue was used for CDT culture (Supplementary Figure 1A).  
Tumours developed from CDT of fresh GL261 GBM were detectable by MRI on day 8 p.i., 
while tumours grown from CDT obtained from frozen GL261 GBM were detectable on day 10 p.i., 
resulting in a slightly longer survival than the group implanted with freshly disaggregated tumours. Both 
achieved full penetrance. Further details on volumes and survival can be can be found in the 
Supplementary Material file (Supplementary Results section and Supplementary Figure 2, as well as 
Supplementary Table 2, respectively).  
Generation of tumours from CDT obtained from S912 GEM  
The MRI screening of the GEM colony [25,26] detected a brain mass in the S912 mouse (S912 
being a unique alphanumeric identifier for animals in our research group), female, by 14 weeks of age, 
-v-erbB transgene and heterozygotic KO for inK4a-Arf (+/-) [7]. The T2W images 32 days 
after the initial detection showed a circumscribed mass (about 22 mm3 in volume) in the rostral 
diencephalon (Supplementary Figure 3A). The CE-MRI T1W studies (Supplementary Figure 3B-3C) 
showed a partially disrupted BBB, indicating an heterogeneous mass. The histopathological diagnosis at 
day 61 post detection was anaplastic OA - of WHO grade III (please check Supplementary Figure 4 for 
further details). Supplementary Figure 1B shows CDT aggregates cultured from this freshly resected 
tumour.  
MRI assessment of tumour growth and penetrance estimation  
 Fresh CDT 
Mice implanted with fresh CDT had 55% of tumour incidence during the monitoring period of 3 
months. Masses showed two distinct growth patterns and were classif
(evolution similar to GL261 CDT tumours) latency  (delayed detection (25±33 days) 
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with respect to GL261 CDT tumours (day 8)). An arbitrary cut-off boundary at 16 days was chosen for 
this. Table 1 summarises average time of first detection and final tumour volume.  
 Frozen CDT  
All animals of this group developed masses with detection spread out in time, having a more 
irregular appearance (Figure 1B and 1C) in comparison to those generated by GL261 cells or fresh S912 
CDT. Most masses were detected between day 14 and 21 p.i., although some tumours were detected 
much later, after 8 months p.i. Tumour doubling time also varied, as in the group implanted with fresh 
CDT (Table 1). As previously, animals were divided into different groups based on tumour growth 
kinetics - long latency
intermediate latency
of time (e.g. 10 weeks for the Gc15-S912 mouse) until they started growing again. 
to masses detected not earlier than day 53 p.i. and tumour evolution ranging between 12 29 days after 
then.  
 Masses intermediate long latency  or associated to 
ventricles (Figure 1D), and this also applies to frozen S912 tumour-derived masses. 
CDT obtained from frozen tumour  
The evolution of tumours from this group mostly resembled the GL261 standard tumours growth 
pattern (Table 1 and reference [27]), apart from two animals: one developed an intermediate latency
tumour type and another one a long latency  tumour type (detection at day 80 p.i.). Tumour incidence 
was 100%, and in most mice, the initial mass was detectable by T2W MRI on the day 10 p.i. 
MRS 
Details about MRS results showing correlation between peak height ratios and tumour 
growth/progression can be found in Supplementary Tables 3 and 4.  
MRSI 
Data from PE-MRSI using DMSO were used to produce maps of differential DMSO 
accumulation. Figure 2A-D illustrates an example of the , showing that DMSO 
accumulates essentially in the internal area of the tumour. At this time point, the tumour had intact BBB 
(Figure 2E), compatible with low-intermediate grade characteristics. 
Pattern recognition 
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Pattern recognition analysis was used to classify voxels from the glucose-perturbed MRSI 
matrices from normal brain parenchyma, ODG (grade II) or GBM (grade IV) using the classifier available 
at our group for this discrimination [28]. Nosological maps for two mice are presented in Figure 3. The 
MSRI based classifier for tumour G1-S912 on day 39 p.i. shows an heterogeneous pattern compatible 
with transition between grade II, with ODG component, and grade IV. As this classifier did not contain 
grade III class cases, the classification could suggest an heterogeneous high grade glioma with 
oligodendroglial component. Histopathology for G1-S912 was anaplastic oligodendroglioma (WHO 
grade III). BBB status was still intact on day 28 p.i. (not shown). For tumour Gc26-S912 (day 35 p.i.) the 
PE-MRSI pattern and nosological image indicated a GBM, which was indeed the final histopathology 
diagnostic. 
Survival 
The survival of each group is shown in Figure 4 and Supplementary Table 2. Significant 
differences ( in survival of mice implanted with CDT from S912 tumour were found in 
comparison with animals implanted with either cultured GL261 cells or GL261 CDT. Up to a 4.3-fold 
increase in the standard GL261 average survival was found. 
Histopathology Studies 
The original S912 tumour, as well as 48 out of 54 tumours generated from it, underwent 
histopathological analysis. From the 16 animals with tumours developed from fresh CDT, 12 were 
diagnosed as grade III: 8 anaplastic ODGs and 4 OAs (see Supplementary Results and Histopathology 
Studies section for histopathological descriptions). The remaining 4 tumours were saved for future CDT 
culture/transplantation, and no histopathological analysis has been performed. The diagnosis for 27 out of 
29 animals implanted with frozen CDT and for all 9 mice implanted with CDT from frozen S912 tumour 
showed clear progression, being classified as grade IV GBM. Samples of two animals could not undergo 
histopathological analysis due to insufficient tissue integrity. 
Genotype check 
Detailed results/discussion for the genotype assessment can be found in Genotype check sections 
in Supplementary Results and Supplementary Discussion).  
DISCUSSION 
Disaggregated tumour model using CDT from GL261 
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The GL261 murine glioma was used for optimization studies because it is a well characterised 
model with reproducible growth pattern [11,23]. The disaggregation technique of solid tumour tissue has 
been widely used for establishment of new glioma cell lines [29]. In this work, GL261 CDT were cultured 
and, upon implantation, resulting similar to the standard GL261 tumour model regarding penetrance, 
growth pattern and survival time (Supplementary Figure 2 and Supplementary Table 2). This is in 
agreement with studies that produced  from cultured GL261 cells and did not find 
significant differences in survival time between animals implanted with 5x104 cells from GL261 
 (23.4±4.6 days) and those implanted with the same amount of GL261 cells directly from 
cell culture (29.8±6.4 days) [30]. However, when the concentration of the inoculum used decreased, cells 
from  confirmed a more aggressive behaviour with significantly reduced survival time. 
This was not studied in our case. 
Additionally, our results proved that culture of CDT from a frozen GL261 mass was also 
feasible, reaching full tumour penetrance. This finding is in line with studies demonstrating that using 
frozen tissue for establishment of stable outgrowing cells does not significantly decrease take rates in 
comparison to fresh material [31]. This should be useful, as it is not always possible to work with freshly 
excised masses. Still, authors in [31] did not evaluate performance in allograft transplantation 
experiments. 
Disaggregated tumour model from a GEM anaplastic OA: S912 tumour 
Applying the optimized method to a GEM fresh tumour showed a penetrance of 55% in 
comparison to ~90% for spontaneous tumour development described by providers [7], but clearly higher 
than penetrance found in our lab ( 16%, [25,26]). This penetrance was also much lower than 96% for the 
standard GL261 model (GABRMN unpublished results, n=832) or full penetrance in GL261 setup 
experiments from this work (n=6). When repeating studies with frozen CDT from GEM or frozen GEM 
tumour, the penetrance increased to 100%. A possible explanation for this would be that culturing, 
freezing, thawing and growing helps selecting for a more aggressive cellular subtype, possibly 
accumulating additional mutations, favouring higher grade tumours development. This would be in line 
with literature, which describes that it is difficult to obtain a low/intermediate grade stable cell line. Thus, 
Shimada et al. [32] showed that aggressive tumours allow to establish stable cell lines from primary 
culture, while it proves difficult with non-aggressive tumours. Authors in [32] also suggested that the 
mutational status of p53 and MDM2 plays an important role in development of stable tumoural cell lines 
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for tumour generation. Other authors have reported that expansion of tumour cells via in vitro culture can 
affect the characteristics of developed masses in comparison with the original tumour. In this respect, 
Barker et al. [33], after 6 months of cell culture, observed that implanted tumours originally diagnosed as 
astrocytoma with anaplastic features (grade III), were later classified as mixed GBM/sarcoma or 
gliosarcoma (grade IV). Halfter et al. [34] established cell lines from a mixed oligoastrocytoma and an 
astrocytoma, both of grade II/III, and only the latter induced tumour in athymic mice. Onda et al. [35] 
established glioma cell lines from two surgical specimens obtained from the same patient at different 
times; one was derived from the primary tumour (slightly anaplastic astrocytoma, grade II/III), while 
another was from the recurrent tumour (GBM, grade IV) and subcutaneous tumours developed only after 
inoculation of the higher grade cells into nude mice. However, in contrast to what was described in [32], 
neither of the cell lines generated in [35] had alteration in p53 mutational status.  
On the other hand, it has been reported that cryopreserved human spheroids  retain their 
histological characteristics after thawing [36] and when xenografted into nude mice after defreezing, their 
essential phenotypic traits and gene expression profiles do not change significantly [37,38]. However, 
spheroids  reported in both studies were originally derived from GBM, already grade IV tumour. 
Therefore, further work is needed to clarify the cause of the recorded progression in our case, and the 
mutational status of driver genes may need to be evaluated.  
Additionally, survival of animals in nearly all groups implanted with CDT from S912 was larger 
than for the GL261 model (Supplementary Table 2). There was a significant difference between S912 
tumours derived from fresh CDT and tumours derived from fresh GL261 CDT, as well as between frozen 
CDT long latency group tumours and fresh S912 CDT derived tumours, which may be of interest for 
therapy response studies in our group [27].  
Non-invasive MR monitoring of S912 CDT-derived tumours 
The MRI/MRS/MRSI acquisition of S912-derived tumours allowed in vivo assessment of their 
grade, later confirmed by histopathology. A discussion about MRS results can be found in the 
Supplementary Material file. The PE-MRSI derived classifier allowed non-invasive evaluation of 
tumours. Tumours derived from fresh S912 CDT were classified as ODG or mixed ODG/GBM, pointing 
to heterogeneous tumours with transition regions from grade II/III to grade IV. A classifier incorporating 
grade III cases would have been required, but it is not yet available. On the other hand, most of tumours 
from groups E and F were classified as GBM, in line with their histopathological diagnosis.
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Furthermore, the information obtained from PE-MRSI with DMSO could be useful for those 
developing new transplantable models for preclinical studies. DMSO is confirmed to serve as a contrast 
agent for early brain tumour detection (Figure 3), independent of their BBB integrity as already proposed 
[21]. This could be useful for therapy monitoring and for evaluating non-invasively local heterogeneities 
associated with progression or therapy response [27], something anatomic MRI alone cannot provide 
[39]. Further studies are needed in order to validate these findings with histopathological features 
associated with tumour relapse/response. 
Conclusions 
We successfully established a new transplantable model of GBM with significantly slower 
growth and higher survival time with respect to the standard GL261 model, and with significantly higher 
penetrance than the original GEM colony. The fact that the S912 mass, used for CDT culture, was 
originally diagnosed as anaplastic OA (grade III) and that the procedures related to CDT culture 
generation, freezing and transplantation produced a progression to grade IV GBM, makes the developed 
transplantable model qualify as a potential secondary GBM model, which may be of interest in future 
therapy monitoring protocols.  
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TABLES  
Table 1 Number of animals assigned into each group, time of initial tumour detection, average final 
volume and doubling time of masses 
Animal group 
No of 
mice 
Time of first mass 
detection by MRI 
(days p.i.) 
Final volume 
(mm3) a 
Average 
doubling 
time (days) 
Standard GL261 6 6 195 ± 40.0 2.4 ± 0.3 
Fresh GL261 CDT 6 8 101 ± 26.0  2.1 ± 0.3 
CDT from frozen GL261 
tumour  
7 10 119 ± 32.0 2.3 ± 0.3  
Fresh S912 
CDT 
Short latency d 9 9 101.4 ± 58.9 4.3 ± 0.4 
Intermediate 
latency d 
7 
25 ± 33 
(between 16-97) 
181.0 ± 74.0 9.8 ± 12.1* 
Frozen S912 
CDT 
Short latency 13 15 ± 3 106.2 ± 59.4 3.4 ± 1.3 
Intermediate 
latency 
9 21 ± 3 139.1 ± 71.2 b 9.1 ± 2.8* 
Long latency d 5 
75 ± 104 
(between 27-253) 
155.2 ± 50.1 9.5 ± 4.8* 
CDT from frozen S912 tumour  9 10 ± 3 c 181.0 ± 74.0 3.5 ± 1.6 
a This measure is a rough estimate, because some animals were screened before their death/sacrifice (up to 
8 days) 
b Excluding Gc29-S912, because its last volume check was done 27 days before its death. 
c Excluding Gtc6-S912, in which the abnormal mass was only detected by MRI on the day 80 p.i.  
d  
* There was a significant difference between intermediate/long latency and short latency groups 
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FIGURES
 
Fig. 1 Coronal T2W MRI of mice brains with different appearance of tumours, depending on type of cells 
implanted A) tumour C482 generated with standard GL261 cells (from the repository of C57BL/6 mice 
with GL261 GBM explored in the group in the period 2010-2011), 15 days post tumour detection B) 
tumour G10- CDT, 19 days post tumour detection 
C) tumour Gc5- CDT, 20 days post tumour 
detection D) ventricular obliterating tumour Gc8-S912 
frozen S912 CDT, 46 days post tumour detection 
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 Fig. 2 Representative DMSO-MRSI of the animal G6-S912 acquired at TE 14ms at 34 days p.i.: A) VOI 
superimposed with the reference image (T2W MRI). B) Enlargement of VOI: black dotted line labels the 
tumoural mass and black squares 1 and 2 correspond to the voxels of the matrix from which SV spectra 
were extracted and shown in D). C) Color-coded intensity map representing the relative DMSO signal (as 
described in [21]) detected at 66 minutes after its i.p. administration. D) Spectra of voxels marked as 1 
(low accumulation zone) and 2 (high accumulation zone) in the MRSI grid shown in B before (black 
spectrum) and 66 minutes after the administration of DMSO (red spectrum). Cho: choline containing 
compounds, Cr: total creatine, NAA: N-acetylaspartate, Lac/ML: Lactate/mobile lipids. E) Coronal T1W 
MRI pre- (left) and post- (middle) contrast administration and subtraction of the two previous images 
(right) of the animal G6-S912 acquired 34 days p.i.  
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 Fig. 3 Pattern recognition analysis for two representative animals from groups D and E of Supplementary 
Table 1, implanted with fresh CDT, G1-S912 (top) at day 39 p.i. and frozen CDT, Gc26-S912 (bottom) at 
day 35 p.i. A) VOI superimposed with the reference image (T2W MRI). B) Enlargement of VOI shown in 
A with spv for short TE in red. C) Nosological maps. Blue voxels are assigned to normal brain 
parenchyma (NB), red voxels to GBM and green voxels to ODG. Tumour boundaries from T2W images 
are marked with a white dotted line 
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SUPPLEMENTARY MATERIAL FOR:  
DEVELOPMENT OF A TRANSPLANTABLE GLIOMA TUMOUR MODEL 
FROM GENETICALLY ENGINEERED MICE. MRI/MRS/MRSI 
CHARACTERISATION  
 
Magdalena Ciezka, Milena Acosta, Cristina Herranz, Josep M. Canals, Martí Pumarola, Ana Paula 
Candiota, Carles Arús. 
SUPPLEMENTARY METHODS 
CDT Culture 
CDT cultures were obtained by seeding Corning 75 cm2 flasks (Sigma-Aldrich Co.) with 10,000 
cells/cm2 -Aldrich Co.):F12 
(GIBCO) (1:1); supplemented with 30% D-(+)-glucose, 0.2 % heparin, 4 mg/ml bovine serum albumin, 
10 ng/ml fibroblast growth factor (all from Sigma-Aldrich Co.), 0.3 mg/ml glutamine, 50 U/ml 
penicillin/streptomycin, 5 mM HEPES, 1× N2 supplement (all from GIBCO) and 20 ng/ml epidermal 
growth factor (Invitrogen SA)]. Cell cultures were incubated at 37°C in a 5% CO2 atmosphere. 
Every 5 days, CDT aggregates were collected, centrifuged at 1000 g during 7 minutes and 
dissociated by pipetting approximately 40 times with a 100 l of medium using a P100 micropipette and 
re-plated in fresh medium at a density of 10,000 cells/cm2in multi-well plates. All cell cultures were 
incubated at 37°C in a 5% CO2 atmosphere. 
Some CDT aggregates were frozen to check the reliability, robustness and repeatability of 
generated cells for transplantation purposes. For this, two days after disaggregation and cultivation, CDT 
were centrifuged and transferred to the freezing medium: 90% Complete Medium with 10% DMSO 
(Sigma Aldrich Co.). The cells (range 30,000  100,000) were loaded into a cryovial and frozen (at the 
ford, UK), and then 
stored in liquid nitrogen. When needed for further use, CDT aggregates were rapidly thawed in a water 
bath at 37°C, washed twice in DMEM and cells from CDT dissociated and cultured as described above. 
In vivo MRI/MRS/MRSI 
MR studies were carried out at the Unit 25 of NANBIOSIS, a joint NMR facility of the 
Universitat Autònoma de Barcelona and CIBER-BBN (Cerdanyola del Vallès, Spain) with a 7T 
horizontal magnet (BioSpec 70/30, Bruker BioSpin, Ettlingen, Germany) equipped with actively shielded 
gradients (B-GA12 gradient coil inserted into a B-GA20S gradient system) and a quadrature receive 
surface coil, actively decoupled from a volume resonator with 72 mm inner diameter. 
Mice were placed in the scanner bed and anesthetized with 0.5-2.0% isoflurane in O2, keeping the 
respiratory frequency at 60-80 breaths/min. The body temperature was controlled using a recirculating 
water system incorporated to the animal bed, measured by a rectal probe and maintained between 37-
38ºC, except in the case of PE-MRSI glucose studies, when the temperature was maintained between 28.5 
- 29ºC. Breathing and temperature were constantly monitored (SA Instruments, Inc., New York, USA). 
MRI acquisition 
-v-erbB / inK4a-Arf (+/-) transgene/KO, as well as GL261 tumour-bearing 
mice were screened by acquiring high resolution coronal T2W images (TR/TEeff = 4200/36 ms) using 
RARE (Rapid Acquisition with Relaxation Enhancement) sequence to detect brain tumour presence and 
monitor its evolution stage. The acquisition parameters were as follows: turbo factor, 8; field of view 
(FOV), 19.2 x 19.2 mm; matrix, 256 x 256 
0.5 mm; inter-ST, 0.6 mm; number of averages (NA), 4; total acquisition time (TAT), 6 min and 43 s.  
SV-MRS acquisition 
Once tumours reached a volume sufficient for setting a voxel of the size (2 - 3 mm)3 without 
contaminating the metabolic profile with normal brain parenchyma, SV spectra were acquired at short and 
long echo time (TE), 12 and 136 ms respectively, using PRESS localization and VAPOR water 
suppression [1], and using the parameters described in [2]: spectral width (SW), 4006.41 Hz; TR, 2500 
ms; NA, 128; TAT, 5 min and 30 s. 
Contrast Enhanced MRI (CE MRI) 
Animals were studied by CE MRI to evaluate BBB integrity by acquiring standard T1W images 
(TR/TE=350/8.5ms) before and 20 minutes after intraperitoneal (ip) injection of gadoterate meglumine 
(DOTAREM, Guerbet, Roissy, France) as a bolus (200 µl, 50µmol/ml in saline).  
MRSI and PE-MRSI 
A total of thirty-seven tumour-bearing mice were studied by PE-MRSI with DMSO 
administration [2] and/or (according to the BioSpec scanner availability) by PE-MRSI with glucose in 
hypothermia [3]. Supplementary Table 3 states the number of animals and explorations carried out for 
each condition. Both substances used in PE-MRSI studies were injected ip as a bolus (10 µl per g of 
animal, 10% (v/v) DMSO and 25% (w/v) D-glucose in saline, respectively), while the animals were 
inside the magnet, to avoid re-shimming needs. 
For the PE-MRSI with DMSO, a coronal T2W high resolution reference image and 14 ms TE 
basal MRSI were initially acquired. DMSO was then injected, followed by three repeated 14 ms TE 
MRSI acquisitions. For the PE-MRSI with glucose in hypothermia studies, a coronal T2W high resolution 
reference image and two reference scans were initially acquired, one with 14 ms TE, followed by 136 ms 
TE. Then, hyperglycemia was induced and consecutive MRSI scans were acquired as follows: 14 ms TE, 
14 ms TE, 14 ms TE, 136 ms TE and 14 ms TE.  
Experiments were performed using a 2D CSI (Chemical Shift Imaging) sequence with PRESS 
localization, where: FOV, 17.6 x 17.6 mm; ST, 1 mm: Volume of Interest (VOI), 5.5 x 5.5 x 1.0 mm, 
positioned in the way that most tumour was covered, and including a part of the nearby 
normal/peritumoural brain parenchyma; TR, 2500ms; SW, 4006.41Hz; NA, 512; TAT, 21m 30 s.  
Water suppression was performed with VAPOR, using a 300 Hz bandwidth. Linear and second 
order shims were automatically adjusted with FASTMAP in a 5.8 x 5.8 x 5.8 mm volume which 
contained the VOI region. Six saturation slices (ST, 10 mm; sech-shaped pulses: 1.0 ms/20250 Hz) were 
positioned around the VOI to minimize outer volume contamination in the signals obtained. Spatial 
after Fourier interpolation to a 32 x 32 matrix, as described in [3].  
MR data post-processing 
Tumour volume calculation 
Tumour volumes for mice in groups of interest were calculated from T2w high resolution 
horizontal images using equation (1): 
 Eq. (1), 
where TV is the tumour volume, ASx is the number of pixels contained in the region of interest delimited 
by the tumour boundaries in each slice of the MRI sequence, ST is the slice thickness (0.5 mm), IT is the 
inter-slice thickness (0.1 mm) and 0.0752 is the individual pixel surface area (mm2). 
The tumour area was calculated in pixels in each slice, using the Paravision 5.0 software (Bruker 
BioSpin, Ettlingen, Germany) and an automated system for generating regions of interest (ROIs).  
Calculation of tumour doubling time  
Doubling time (DT) of abnormal masses was calculated using equation (2) as in [4]:  
       Eq. (2), 
where T-T0 indicates the length of time between two measurements and V0 and V denote the tumour 
volume at two points of measurement, the initial and the final, respectively.  
MRS post-processing 
In vivo MR SV spectra were processed with the TopSpin v1.3 software (Bruker Daltonik, 
GmbH): Lorenzian filter, 4 Hz of line broadening before Fourier transformation, manual zero- and first-
order phase correction were applied and chemical shift was referenced to total creatine (3.03 ppm). The 
spectra were exported in ASCII format and analysed with the software R v2.15.2 (The R Foundation for 
Statistical Computing) using home-written scripts for UL2 normalization [5] (as per equation 3) and 
average spectra and SD calculation. Spectral metabolite heights for major resonances were calculated 
from 0.5 to 4.5 ppm for each spectrum.  
     Eq. (3), 
where  is the normalized intensity for each point of the spectrum and  is the initial intensity 
for each point between 0 and 4.5 ppm 
MRSI post-processing  
MRSI data were post-processed essentially as described in reference [3]. Briefly, data were 
initially pre-processed at the MR workstation with ParaVision 5.0 (Bruker BioSpin), and then post-
processed with 3D Interactive Chemical Shift Imaging (3DiCSI) software package (courtesy of Truman 
Brown, Ph.D., Columbia University, New York, NY, USA) for line broadening adjustment (Lorentzian 
filter, 4 Hz), zero-order phase correction and exporting the data in ASCII format.  
Dynamic MRSI processing Module (DMPM) [6] running over MatLab (The MathWorks Inc., 
Natick, MA, USA) was used to align all spectra within each MRSI matrix (using the choline containing 
compounds peak as reference, 3.21 ppm), quantify the relative peak intensity changes (2.72 ppm for 
DMSO and 3.43 ppm for glucose) and display these changes as color-coded maps (10 x 10 voxels). The 0 
 4.5 ppm region of each spectrum in the MRSI matrix was individually normalized to UL2 and the 
normalized matrix was exported in ASCII format for performing the pattern recognition (PR) analysis. 
Pattern recognition 
The pattern recognition analysis was used to classify which voxels from the glucose-perturbed 
MRSI matrices corresponded to normal brain tissue, ODG or GBM, and it was carried out using 
SpectraClassifier software [7] (available at http://gabrmn.uab.es/sc) and a previously developed classifier, 
as described elsewhere [8]. Each individual voxel in the MRSI grid was referred to as spectral vector 
(spv) and considered as an individual case. The result obtained was represented as colour-coded 
nosological maps for each matrix.  
Tissue preservation for post-mortem procedures 
In vivo MR studies and follow up of the tumour progression took place until animals died or 
were sacrificed, due to animal welfare standard protocol, by cervical dislocation. The brains of 49 mice in 
total (S912 and its derivatives) were excised and fixed in 4% formaldehyde and embedded in paraffin. 
Transversal sections 5 µm thick were cut and analysed by classical Hematoxylin-Eosin staining, as well 
as by immunohistochemistry analysis for oligodendrocyte transcription factor (Olig2) protein as 
oligodendroglial marker and glial fibrillary acid protein (GFAP) as astroglial marker. Classification and 
grading of tumours were performed according to the criteria defined by the World Health Organization 
(WHO) human classification for central nervous system tumours [9]. 
In case of S912-derived tumours with an apparent low/intermediate grade by MRI/MRSI, see 
results, (i.e. no BBB breakdown; MRS SV pattern) (n=5), these were extracted and halved  one part was 
used for histopathological analysis, while another part was frozen in liquid nitrogen in cryotubes 
containing 1ml of 10% DMSO in Phosphate Buffered Saline (PBS) for future disaggregation and 
potentially obtaining second generation of CDT culture. Tumours from randomly chosen animals (n=7) 
were also used to perform genotype check. 
Genotype check 
Transgene presence and knock-out mutations in the GEM S912 mouse were confirmed by PCR 
(polymerase chain reaction) analysis according to slight modifications of the protocols kindly provided by 
Dr David Goldberg (University of California San Francisco, USA) and Dr Dave Sims (MMHCC-NCI, 
USA). Briefly, DNA was extracted overnight at 55ºC from a tail fragment of the mouse with a standard 
lysis solution: 50 mM Tris-HCl pH = 8, 1 mM EDTA, 0.2% SDS, 20 mM NaCl, 100 mg l-1 proteinase K. 
For S100b-v-ErbB amplification, primers (all obtained from Thermo Fisher Scientific GmbH, Ulm, 
-CTCACAGCAATCTCAAAGCTCCCC- -
AGCCTCCAAAGTCAGGTTGATGAGC-  in [10]. For Ink4a-Arf (+/-) three 
-GTGATCCCTCTACTTTTTCTTCTGACTT- -
CGGAACGCAAATATCGCAC- - GAGACTAGTGAGACGTGCTACTTCCA-
conditions were as follows: one cycle of 95°C for 5 min followed by 29 cycles at 95°C for 1 min, 60°C 
for 30 s, 72°C for 2 min and finished with one cycle at 72°C for 10 min. Selected S912-derived tumours 
were checked for the presence of the transgene and knock-out mutations by the same extraction and PCR 
procedure, performed on a piece of tumour, to confirm the accordance of the genotype with the original 
S912 GEM. A total of 9 animals were analysed: 4 animals implanted with CDT cultured from freshly 
disaggregated S912 tumour, 3 animals implanted with previously frozen S912 CDT and 2 animals 
implanted with CDT cultured from a frozen piece of S912 tumour.  
Statistical analysis 
The statistical analysis was carried out using IBM SPSS Statistics v.20 software. The survival 
rate of treated and untreated mice was calculated using Kaplan-Meier analysis. Metabolite height ratios 
from SV MRS spectra were inspected for normality with the Kolmogorov-Smirnov test, compared using 
-test for paired samples and the Mann-Whitney U-test was applied to non-normal 
distributions, while variance homogeneity was studied with the Levene's test. Significance level was set 
to 0.05.  
SUPPLEMENTARY RESULTS  
Passage of tumours obtained from disaggregation of GL261 GBM 
GL261 tumour bearing mice were sacrificed once masses reached a volume of 140±20 mm3 
(n=6, day 18±2 p.i.) and tumour tissue was used to generate CDT cultures (Supplementary Figure 1A).  
CDT obtained from fresh GL261 GBM 
Tumours were detectable by MRI on the day 8 p.i. in all implanted mice and had a mean survival 
of 21±3 days (Supplementary Figure 2). The final mean volume of those tumours was 101±26 mm3, 
significantly smaller (p=0.049) in comparison to 169±59 mm3 in control GL261 tumours from our group 
[11]. The penetrance obtained was 100%.  
CDT obtained from frozen GL261 GBM
Abnormal masses were detectable by MRI on the day 10 p.i., resulting in a slightly longer 
(although not significant, p=0.106) survival (25±2 days) in comparison with the group implanted with 
freshly disaggregated tumours (Figure 4, Supplementary Figure 2 and Supplementary Table 2). The 
penetrance was 100% and the mean final tumour volume was of 119±32 mm3 , non-significantly different 
from control GL261 (p=0.078) and tumours generated with fresh CDT from GL261 tumour (p=0.295). 
CE-MRI studies 
Regarding the animals implanted with fresh S912 CDT, 12 out of 16 animals were studied with 
CE-MRI. It was observed that 7 out of 8 animals had intact BBB during the initial mass development 
(average volume on day 28 p.i. 32±9 mm3, n=8); 2 out of those 7 were also studied at the final stages of 
tumour development (average volume on days 39 and 48 p.i, 136±33mm3) and displayed compromised 
BBB (Supplementary Figures 5 and 6). The remaining 4 animals had compromised BBB at an average 
tumour volume of 144±57 mm3 (between days 40-48 p.i.).  
For mice implanted with frozen CDT (n=29), animals were studied at the initial stages of mass 
development (average volume between day 21 and 30 p.i. 23±14 mm3, n=27); 22 of them displayed 
compromised BBB, while for 5 mice, all from the 
tumour volumes were 22±13 mm3 and 25±23 mm3, respectively), but no follow-up CE-MRI was 
acquired. The remaining 2 animals died before the CE-MRI exploration, therefore their BBB status was 
unknown. 
In the last batch of mice implanted with CDT obtained from a frozen S912 tumour piece, 3 out of 
9 animals had intact BBB (average volume at the CE-MRI exploration 25±3 mm3), but no follow-up 
explorations were performed. The masses with compromised BBB (n=6) were on average 33±31 mm3 
tumour volume.  
MRS 
The average spectra for tumours from each group of mice at short and long TE can be seen in 
Supplementary Figures 7 and 8, while average peak height ratios at both TEs analysed for animals 
implanted with CDT are presented in Supplementary Tables 4 and 5. In the latter it can be seen that SL 40 
p.i. compared to the day 18 p.i. tumours, there was a statistically significant increase of Cho/Cr and 
ML/Cr ratios, suggesting progression to a more aggressive status, while comparing SL tumours at day 18 
and 21 p.i., these changes were not so apparent. These pattern differences were also evident amongst 
tumours derived from fresh S912 CDT (grade III tumours, see histopathology results section) and those 
derived from frozen S912 CDT or CDT obtained from frozen S912 tumour (WHO grade IV tumours, as it 
will be reported in histopathology section). 
MRSI 
Apart from PE-MRSI using DMSO, the spectral pattern of GEM was also perturbed with 
hyperglycaemia to produce maps of D-glucose (at SET) or lactate (at LET) accumulation as in [3]. 
Supplementary Figure 9 shows the mentioned maps for the the animal G6-
 with PE-MRSI using DMSO previously presented in Figure 2). The "glucose 
accumulation" map suggests a strong heterogeneity of glucose arrival /consumption within the tumour. 
Histopathology Studies 
Grade III anaplastic ODG displayed a solid growth pattern composed of polygonal cells with 
pleomorphic nuclei corresponding to a medium grade of anisokaryosis. The tumour cells presented an 
evident eosinophilic and poorly delimited cytoplasm. Mitotic cells were evident. Moreover, some cells 
displayed picnotic nuclei, but clear necrotic foci were not observed. Proliferative capillaries and 
glomeruloid vessels together with multifocal bleedings were present. Furthermore, tumour cells also 
infiltrated surrounding nervous tissue.  
OA presented oligodendrocytes (expressing Olig2) and astrocytes (expressing GFAP) intimately 
mixed in a solid growth pattern. They showed histological features of malignancy (increased cellularity, 
anisokariosis, pleomorphism and increased mitotic activity). Tumour cells infiltrated surrounding nervous 
tissue. 
The growth pattern of GBM was also solid and the tumour was formed by polygonal cells with 
basophilic loose chromatin nuclei that showed a high grade of anisokaryosis. In this tumour type, mitotic 
cells were abundant and more evident than in the other tumours. The tumour also showed an abundant 
diffuse basophilic secretion throughout the whole mass. Typical pseudopalisading necrotic areas 
characteristic of GBM were present. Adjacent nervous tissue was generally compressed by the tumour, 
but focally infiltrated by neoplastic cells. 
Genotype check 
Nine randomly chosen animals with implanted CDT had the genotype of their tumours checked 
in order to confirm the accordance with the original genotype. All tumours checked presented the 
expected transgene (Tg; S100B-v-erbB) as in the initial S912 mouse. However, three of the analysed 
masses presented loss of heterozygosity for the knockout gene (Ink4a-Arf (+/-)), being homozygotic (KO-
/-). Two of these animals belonged to the group implanted with fresh CDT  while 
 injected with frozen CDT.  
SUPPLEMENTARY DISCUSSION  
Genotype check 
Considering the genotyping of random animals, three animals out of nine presented loss of 
heterozygosity for Ink4a-Arf. The homozygous deletion of Ink4a-Arf in humans is often associated with 
malignant progression in high-grade gliomas [12,13] being also one of the most frequent mutations found 
in human gliomas [14,15] associated with short survival times [12]. In transgenic mice it has been 
described that animals homozygous for loss of Ink4a-Arf, develop tumours with similar incidence, but 
with decreased latency and survival in comparison to heterozygous animals [10]. In our studies, the 
phenotypic consequences for the loss of heterozygosity for the original S912 knockout were not obvious, 
as the animals with homozygous deletion fe
groups. However, this genomic difference is not negligible and should be taken into account in future 
studies, possibly using a wider gene sequencing approach. 
Non-invasive MR monitoring of S912-derived tumours 
Regarding MRI/MRS/MRSI acquisition of S912-derived tumours, this allowed preliminary in 
vivo assessment of their grade, later confirmed by histopathological analysis. Tumours developed from 
fresh S912 CDT showed features associated with low/intermediate grade glioma (Supplementary Figure 
7), i.e. increased Cho/Cr ratio, decrease in NAA which is usually associated with a decrease of viable 
neurons [16-18], and increased lactate signal and detection of mobile lipids [18,19]; while patterns of 
tumours derived from frozen S912 CDT (Supplementary Figure 8) have clearly higher lactate and mobile 
lipids peaks usually associated with GBM [8]. Additionally, still regarding tumours derived from frozen 
CDT, the decrease in the estimated mI/Gly ratio [20] for intermediate and long latency groups with 
respect to short latency group (Supplementary Table 4) could suggest a metabolic subtype. This decrease 
is not so clear in case of tumours derived from fresh S912 CDT and further ex vivo and in vitro extract 
studies would be needed to clarify it. Although a detailed in vivo analysis of the MRS pattern of GBM 
subtypes is still lacking, ex vivo data obtained by HR-MAS analyses of tumour biopsies suggests that 
human secondary GBM could display a much higher mI content than primary ones [21].  
Besides, other MR studies performed could also help in the non-invasive characterization of the 
GEM-derived transplantable tumours. CE-MRI allowed assessment of the state of BBB integrity and a 
qualitative orientation of a possible transition to higher grade. Mice implanted with fresh S912 CDT 
studied at the initial stages of tumour development (average volume 32±9 mm3) had mostly intact BBB (7 
out of 8). When CE-MRI was repeated for 2 of these tumours at the longer growth time (average volume 
136±33mm3), they displayed contrast intake (Supplementary Figure 5 and 6), which suggested an 
undergoing transition of grade III to a higher grade IV. The progression in the tumour grade was more 
evident for tumours derived from frozen samples as the BBB was compromised at earlier stages (22±13 
mm3) in 22 out of 27 animals investigated by CE-MRI.  
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Supplementary Table 1 Distribution of experimental animals depending on the source of cells used for 
each tumour generation protocol, and identifiers of animals in each group 
Group No. of animals 
Source of cells for tumour 
generation 
Alphanumeric identifier of 
animals in the group 
A 6 Standard GL261 cells 
C(unique number) 
B 6 
CDT cultured  
from fresh GL261 tumour 
C 7 
CDT cultured 
from frozen GL261 tumour 
D 29 
CDT cultured 
from fresh S912 tumour 
G(unique number)-S912 
E 29 
Frozen CDT cultured from fresh 
S912 tumour 
Gc(unique number)-S912 
F 9 
CDT cultured 
from frozen S912 tumour 
Gtc(unique number)-S912 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2 Survival time (days, mean ± SD) of each experimental group of mice. There 
was a significant difference detected between tumours derived from S912 CDT and tumours derived from 
GL261 CDT (*) and between either intermediate or long latency tumours derived from frozen S912 CDT 
and tumours derived from fresh S912 CDT (**). The difference in survival time was non-significant 
between tumours derived from GL261 CDT (either fresh or frozen) and standard GL261 tumour, and 
neither between tumours derived from S912 CDT cultured from a frozen piece of tumour and tumours 
derived from fresh S912 CDT 
Group 
of 
animals 
GL261 
tumours 
(n=6) 
GL261 CDT 
S912 CDT 
From fresh tumour 
From 
frozen 
tumour 
(n=9) 
Fresh CDT Frozen CDT 
Fresh 
(n=6) 
Frozen 
tumour 
(n=7) 
Short 
latency 
(n=9) 
Intermediate 
latency 
(n=7) 
Short  
latency 
(n=13) 
Intermediate 
latency 
(n=9) 
Long 
latency 
(n=5) 
Mean 
survival 
(days) 
19  
± 2.9 
23  
± 2.5 
25  
± 2.4 
40 * 
± 4.9 
61 * 
± 20.6 
41*  
± 10.6 
103 */**  
± 42.4 
163*/**  
± 124.2 
45* 
± 15.3 
 


Supplementary Table 5 Number of animals/PE-MRSI explorations carried out 
Group of animals 
PE-MRSI with 
DMSO 
PE-MRSI with glucose in 
hypothermia 
Group D 11 7 
Group E 18 14 
Group F 4 4 
SUPPLEMENTARY FIGURES  
 
Supplementary Fig. 1 Microscope image of CDT aggregates generated from a fresh piece of A) GL261 
tumour and B) S912GEM tumour after 17 days of culture. Scale bar; 100 m 
 
 
 Supplementary Fig. 2 Average growth curves representing the mean ± SD (vertical bars) of tumour 
volumes grown from implanted: A) GL261 cells (n=6); B) CDT cultured from fresh GL261 tumour 
(n=6), C) CDT cultured from frozen GL261 tumour (n=7). Bars state ± SD of volume at each time point 
of volume measurement 
 Supplementary Fig. 3 Coronal T1W MRI of the S912 mouse brain A) pre- and B) post-contrast 
administration, as well as C) subtraction of the two previous images, acquired at 7T 32 days after initial 
tumour detection. The black arrow in C indicates the area of contrast enhancement 
 
 
Supplementary Fig. 4 Hematoxylin and eosin stained (left side) and glial fibrillary acidic protein 
(GFAP) immunohistochemically stained (right side) characteristic paraffin sections of the S912 anaplastic 
oligodendroglioma tumour of WHO grade III. The neoplastic sample displays a solid growth pattern 
composed of polygonal cells with pleomorphic basophilic nuclei (corresponding to a medium grade of 
anisokaryosis) and an evident and poorly delimited eosinophilic cytoplasm. Moreover, some cells display 
picnotic nuclei. Immunohistochemical analysis is characterized by low levels of GFAP expression 
confined to reactive astrocytes (brown colour), mixed with immunonegative neoplastic cells (original 
magnification x200), bar 50µm.  
  
Supplementary Fig. 5 Changes in contrast uptake and spectral pattern of G4-S912 tumour during its 
growth. A) Coronal T1W MRI pre and post CE at day 20 p.i. (left) and at day 31 p.i. (right). The red arrow 
indicates the zone of contrast uptake. B) Growth curve of the tumour. Black arrows indicate time points 
of the CE studies; while green and red arrows show time points at which SV MR spectra presented in C) 
were acquired. C) Comparison of the spectra acquired at short TE (12 ms) at initial (red) and final (red) 
stages of tumour progression. Cho: choline containing compounds, Cr: total creatine, mI/Gly: myo-
inositol/glycine, NAA: N-acetylaspartate, Lac: lactate, ML: mobile lipids, Tau: taurine 
 Supplementary Fig. 6 Changes in contrast uptake and spectral pattern of G5-S912 tumour during its 
growth. A) Coronal T1W MRI pre and post CE at day 20 p.i. (left) and 31 p.i. The red arrow indicates the 
zone of contrast uptake. B) Growth curve of the tumour. Black arrows indicate time points of the CE 
studies; while green and red arrows show time points at which SV MR spectra presented in C) were 
acquired. C) Comparison of the spectra acquired at short TE (12 ms) at initial (red) and final (red) stages 
of tumour progression. Cho: choline containing compounds, Cr: creatine, mI/Gly: myo-inositol/glycine, 
NAA: N-acetylaspartate, Lac: lactate, ML: mobile lipids, Tau: taurine 
 
 Supplementary Fig. 7 Average UL2 normalized SV MR spectra (± SD, grey shading) at short (12 ms) 
and long (136 ms) TE obtained from (1.5 - 3.0 mm)3 voxels of tumours generated from GEM S912 fresh 
CDT of: A) =9) and 40 (n=7) p.i. 
and of B) 
Ala:Alanine, Cho: choline containing compounds, Cr: total creatine, Gly: glycine, Lac: lactate, mI: myo-
inositol, ML: mobile lipids, NAA: N-acetylaspartate 
 Supplementary Fig. 8 Average UL2 normalized SV MR spectra (± SD, grey shading) at short (12 ms) 
and long (136 ms) TE obtained from tumours generated from frozen GEM S912 CDT (A, B, C) and 
tumours generated from CDT obtained from a frozen piece of GEM S912 tumour (D): A) 
group of animals (n=13), SV acquired between days 21 and 34 p.i., B) 
animals (n=6), SV acquired between days 59 and 77 p.i., C) 
acquired between days 86 and 253 p.i., D) group of animals implanted with CDT obtained from a frozen 
tumour (n=8), SV acquired between day 26 and 80 p.i. Ala: alanine, Cho: choline containing compounds, 
Cr: total creatine, Gly: glycine, Lac: lactate, mI: myo-inositol, ML: mobile lipids, NAA: N-
acetylaspartate. 
 
 
 
 
 Supplementary Fig. 9 Representative PE-MRSI with hyperglycaemia and hypothermia of the tumour in 
the animal G6-S912 acquired at 41 days p.i.: A) VOI superimposed with the reference image (T2W MRI). 
B) Enlargement of VOI: black dotted line labels the tumoural mass and black squares 1 and 2 correspond 
to the individual voxels of the MRSI grid from which SV spectra were extracted and shown in D). C) 
Color-coded intensity map of D-glucose caused pattern increase at 3.43 ppm (14ms TE) acquired at 88 
minutes after glucose administration. D) Spectra of labelled voxels in the matrix (black squares) before 
(black spectrum) and after (red spectrum) glucose administration. The black arrow indicates the transient 
D-glucose accumulation peak at 3.43 ppm (Glc). Cho: choline containing compounds, Cr: total creatine, 
Lac/ML: Lactate/mobile lipids, NAA: N-acetylaspartate 

